Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate

Urologic Clinics of North America

Volumn 30, Issue 2, 2003, Pages 351-362

  Stone, Nelson N ^a,b   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER GRADING; CANCER SURVIVAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW; TREATMENT OUTCOME;

EID: 0037406290     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00185-4     Document Type: Review

References (66)

1. Holm HH, Pedersen JF, Hansen H, et al. Transperineal I-125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
2. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-53.
3. Pasteau O, Degrais P. The radium treatment of cancer of the prostate. Journal d'Urologie (Paris) 1913;4:341-366.
4. Stone NN, Ramin SA, Wesson MF, et al. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 1995;153:1555-60.
5. Stock RG, Stone NN, Lo YC, et al. Post-implant dosimetry for 1-125 prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 2000;48:899-906.
6. Quimby EH. The grouping of radium tubes in packs and plaques to produce the desired distribution of radiation. AJR Am J Roentgenol 1932;27:18-36.
7. Stone NN, Stock RG, DeWyngaert JK, et al. Prostate brachytherapy: improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry. Radiat Oncol Investig 1995;3:185-95.
8. Stock RG, Stone NN, Lo YC. Intraoperative dosimetric representation of the real-time ultrasound guided prostate implant. Tech Urol 2000;6:95-8.
9. Linzer DG, Stock RG, Stone NN, et al. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology 1996;48:757.
10. Stone NN, Stock RG, Parikh D, et al. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. J Urol 1998;160:1722-6.
11. 3: dosimetric analysis of implant quality. Int J Radiat Oncol Biol Phys 2000;46:1199-204.
12. Stone NN, Ratnow ER, Stock RG. Prior transurethral resection does not increase morbidity following real-time ultrasound guided prostate seed implantation. Tech Urol 2000;6:123-7.
13. Bolla M, Gonzalez D, Padraig W, et al. Improved survival in patients with clinically advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
14. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-52.
15. Pilepich MV, Sause WT, Shipley WU, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
16. Kucway R, Vicini F, Huang R, et al. Prostate volume reduction with androgen deprivation therapy before interstitial radiotherapy. J Urol 2002;167(6):2443-7.
17. Stock RG, Stone NN, Yeghiayan P. Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage TI-T2 prostate cancer. Mol Urol 1998;2(3):121-7.
18. Stone NN, Stock RG. Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer. Mol Urol 1999;3(3):239-45.
19. Whittington R, Broderick A, Arger P, et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44(5):1107-10.
20. Blasko JC, Ragde H, Grimm PD, et al. Potential for neoadjuvant hormonal therapy with brachytherapy for prostate cancer. Mol Urol 1997;1:207-11.
21. Stone NN, Stock RG, Unger P, et al. Prostate biopsy results following real-time I -125 brachytherapy. J Urol 2002;167:919.
22. Stone NN, Stock RG, Unger P, et al. Biopsy results following real-time ultrasound-guided transperineal implants for T1-T2 prostate cancer. J Endourol 2000;14:379-84.
23. Stock RG, Stone NN, Kao J, et al. The effect of disease and treatment related factors on biopsy results following prostate brachytherapy: implications for treatment optimization. Cancer 2000;89:1829-1834.
24. Blasko JC, Radge H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocure Hyperthermia Oncology 1987;3:131-9.
25. 125 Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153:1020-5.
26. Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995;32:219-25.
27. Nag S, Ciezki JP, Cormack R, et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2001;51(5):1422-30.
28. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-34.
29. Stock RG, Stone NN, Tabert A, et al. A doseresponse study for 1-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101-8.
30. Potters L, Gao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;50(3):605-14.
31. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
32. Desai J, Stock RG, Stone NN, et al. Acute urinary morbidity following 1-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998;6:135-41.
33. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following I125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335-41.
34. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;7:1035-41.
35. Critz FA, Levinson AK, Williams WH, et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997;49:322-326.
36. Critz FA, Tarlton RS, Holladay DA. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer: I-125 implant followed by external-beam radiation. Cancer 1995;75:2383-91.
37. Iannuzzi CM, Stock RG, Stone NN. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiat Oncol Invest 1999;7:30-5.
38. Cavagnagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate specific antigen following 1-125/Pd-103 brachytherapy for localized prostate cancer. Semin Urol Oncol 2000;18(2):160-5.
39. Grimm PD, Blasko JC, Sylvester JE, et al. 10 year biochemical (prostate specific antigen) control of prostate cancer with 1-125 brachytherapy. Int J Rad Oncol Biol Phys 2001;49:31-40.
40. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46(4):839-50.
41. Dattoli MJ, Wallner KE, Cash JC, et al. Palladium 103 brachytherapy for clinical T1/T2 prostate carcinomas. Int J Radiat Oncol Biol Phys 1997;39:220.
42. Lederman GS, Cavanagh W, Albert PS, et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 2001;49(5):1297-1303.
43. Ragde H, Grado GI, Nadir BS. Brachytherapy for clinically localized prostate cancr: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 2001;54(70):739-47.
44. Stone NN, Stock RG. 8 year treatment results of prostate brachytherapy. J Urol 2002;167:1560a.
45. Lee LN, Stock RG, Stone NN. The role of hormone therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444-52.
46. Ragde H, Abdel-Aziz AE, Snow PB, et al. Ten-year disease free survival after transperineal sonographyguided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
47. Stock RG, Stone NN, Hong S. Is long term hormonal therapy needed with dose escalation in high risk prostate cancer? Results of treatment with 9 months of hormonal therapy, brachytherapy and 3D conformal external beam irradiation. Int J Radiat Oncol Biol Phys 2001;51:2127a.
48. Zeitlin SI, Sherman J, Raboy A, et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998;160:91-6.
49. Bucci J, Morris WJ, Keyes M, et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53(1):91-8.
50. Crook J, Mclean M, Catton C, et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):453-60.
51. Locke J, Ellis W, Wallner K, et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. Int J Radiat Oncol Biol Phys 2002;52(3):712-9.
52. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-82.
53. 125I implantation for localised prostatic carcinoma. Br J Urol 1993;72:470-7.
54. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage TI/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-53.
55. 125I prostate implantation. Int J Radiat Oncol Biol Phys 1994;28:985-90.
56. Stone NN, Stock RG. Prospective long-term analysis of urinary symptoms and quality of life in men with large or small prostates treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48(Suppl):1006.
57. Kang SK, Chou RH, Dodge RK. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53(1):99-103.
58. Han BH, Wallner KE. Dosimetric and radiographic correlates to prostate brachytherapy related rectal complications. Int J Cancer 2001;96(6):372-8.
59. Theodorescu D, Gillenwater JY, Schneider BF, et al. Prostatourethral-rectal fistula following prostate brachytherapy: incidence and risk factors. J Urol 2000;163:1294a.
60. Gelbum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:119-24.
61. Potters L, Torre T, Fearn PA, et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50(5):1235-42.
62. Stock RG, Kao J, Stone NN. Penile erection function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001;165:436-9.
63. Merrick GS, Butler WM, Galbreath RW, et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52(4):893-902.
64. Incrocci L, Koper PCM, Hop WCJ, et al. Sildenafil citrate (Viagra) and erectile function following external beam radiotherapy for prostate cancer: a randomized, double blind, placebo-controlled, cross over study. Int J Radiat Oncol Biol Phys 2001;51(5):1190-1195.
65. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20(2):557-66.
66. Davis JW, Kuban DA, Lynch DF, et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166:947-52.